Post by sam9009 on Jul 14, 2015 16:55:50 GMT -5
Toronto, Ontario (PRWEB) May 21, 2015
Inflamax Research, Inc., today announces the acquisition and ing of a clinical research site in Neptune, New Jersey. The site, which was acquired from a leading CRO, has very experienced core staff and senior management with extensive experience in running complex first-in-man and disease specific Phase 1 studies. The site staff are well trained and have a history of numerous successful audits from the FDA and other regulatory agencies. Inflamax’s robust recruiting group will coordinate the recruitment locally in New Jersey using our proprietary OCRUP system for centralized clinical trial recruitment.
“We are delighted to welcome the staff of Neptune site to the Inflamax family. We look forward to integrating the unit to Inflamax’s robust quality systems that have been thoroughly tested through many successful audits. We intend to focus the site on Phase 1 studies in disease specific patient populations” says Dr Piyush Patel, CEO of Inflamax..”The site will work closely with Inflamax head office groups to provide full service for all studies conducted, including pharmacokinetics, data management, biostatistics and medical writing. Inflamax’s highly regarded Quality Assurance group will audit and ensure the highest quality for all studies conducted at our Neptune site”
“We have had many requests to have a clinical research capability and capacity for our offerings in the United States under FDA jurisdiction. In addition to the respiratory and allergy focus, the experience and resources at Neptune site will now give Inflamax the capability to conduct Phase 1 and 2 studies in other therapeutic areas such as diabetes and CNS specifically Alzheimer’s.
Inflamax Research is a full service global CRO specializing in allergy and respiratory diseases led by world known key opinion leaders. Inflamax has a strong academic background and publishes extensively in peer reviewed journals. Inflamax has experience with conducting large multi-center studies from concept to protocol writing, site management, data management and medical writing. Inflamax’s scientists and clinicians are well known to regulatory authorities and regularly participate in an advisory a role.
Inflamax Research, Inc., today announces the acquisition and ing of a clinical research site in Neptune, New Jersey. The site, which was acquired from a leading CRO, has very experienced core staff and senior management with extensive experience in running complex first-in-man and disease specific Phase 1 studies. The site staff are well trained and have a history of numerous successful audits from the FDA and other regulatory agencies. Inflamax’s robust recruiting group will coordinate the recruitment locally in New Jersey using our proprietary OCRUP system for centralized clinical trial recruitment.
“We are delighted to welcome the staff of Neptune site to the Inflamax family. We look forward to integrating the unit to Inflamax’s robust quality systems that have been thoroughly tested through many successful audits. We intend to focus the site on Phase 1 studies in disease specific patient populations” says Dr Piyush Patel, CEO of Inflamax..”The site will work closely with Inflamax head office groups to provide full service for all studies conducted, including pharmacokinetics, data management, biostatistics and medical writing. Inflamax’s highly regarded Quality Assurance group will audit and ensure the highest quality for all studies conducted at our Neptune site”
“We have had many requests to have a clinical research capability and capacity for our offerings in the United States under FDA jurisdiction. In addition to the respiratory and allergy focus, the experience and resources at Neptune site will now give Inflamax the capability to conduct Phase 1 and 2 studies in other therapeutic areas such as diabetes and CNS specifically Alzheimer’s.
Inflamax Research is a full service global CRO specializing in allergy and respiratory diseases led by world known key opinion leaders. Inflamax has a strong academic background and publishes extensively in peer reviewed journals. Inflamax has experience with conducting large multi-center studies from concept to protocol writing, site management, data management and medical writing. Inflamax’s scientists and clinicians are well known to regulatory authorities and regularly participate in an advisory a role.
